Also, two trials on sirolimus/tacrolimus combinations for acute GvHD prophylaxis over tacrolimus/MTX [20] , [21] suggested protection (OR 0.22; 95%CI 0.05–1.11, NNTB = 5, effect of marginal significance).
← all excerpts
Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.
1
—
—